List of Excipients in Branded Drug RECLAST

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	RECLAST	zoledronic acid	0078-0435	MANNITOL
Novartis Pharmaceuticals Corporation	RECLAST	zoledronic acid	0078-0435	SODIUM CITRATE
Novartis Pharmaceuticals Corporation	RECLAST	zoledronic acid	0078-0435	WATER
Sandoz Inc	RECLAST	zoledronic acid	66758-155	MANNITOL
Sandoz Inc	RECLAST	zoledronic acid	66758-155	SODIUM CITRATE

Reclast Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Reclast is a ready-to-use intravenous zoledronic acid product containing 5 mg of active ingredient in a 100 mL solution. Its inactive-ingredient system is simple: mannitol and sodium citrate. The commercial opportunity is therefore concentrated in manufacturing efficiency, container-closure performance, supply reliability, and service differentiation rather than broad excipient innovation.

Reclast has limited remaining regulatory exclusivity and does not have a meaningful biosimilar pathway because zoledronic acid is a small-molecule drug. Generic competition is established. New entrants would face a price-sensitive injectable market in which formulation changes can increase regulatory risk without creating substantial clinical differentiation.

What excipients are used in Reclast?

Reclast uses mannitol and sodium citrate as its principal excipients.

Product attribute	Reclast specification
Active ingredient	Zoledronic acid
Strength	5 mg per 100 mL
Dosage form	Intravenous solution
Administration	Intravenous infusion over at least 15 minutes
Mannitol	495 mg per 100 mL
Sodium citrate	30 mg per 100 mL
Preservative	None listed
Primary commercial function	Ready-to-use single-dose infusion
Manufacturer of reference product	Novartis
FDA application	NDA 021817

The product labeling identifies mannitol and sodium citrate as inactive ingredients. The solution is supplied in a 100 mL container and is intended for single-dose intravenous administration.[1]

Why does Reclast use mannitol?

Mannitol performs several formulation functions:

• It contributes to tonicity.
• It supports the physical properties of the infusion solution.
• It is compatible with a ready-to-use aqueous parenteral presentation.
• It avoids the need for more complex excipient systems.

At 495 mg per 100 mL, mannitol is present at a substantially higher mass than the buffer component. The formulation does not depend on surfactants, preservatives, polymers, or solubilizing agents commonly used in more complex injectable products.

Mannitol is commercially available from multiple pharmaceutical excipient suppliers. The principal qualification issues are parenteral grade, bioburden, endotoxin control, particulate profile, supply continuity, and consistency between manufacturing sites.

Why does Reclast use sodium citrate?

Sodium citrate acts primarily as a buffering and pH-control excipient. Zoledronic acid is a highly polar bisphosphonate with acid-base properties that require controlled solution conditions for stability and product performance.

The citrate system must be controlled for:

• pH range
• buffer concentration
• ionic strength
• compatibility with the container
• precipitation risk
• stability during storage
• compatibility with the infusion line and administration environment

A different buffer system may be technically feasible, but a formulation that departs from the reference product can create an ANDA sameness issue or require a 505(b)(2) strategy.

What is the FDA regulatory status of Reclast?

Reclast received FDA approval in 2007 under NDA 021817 for specified osteoporosis and Paget's disease indications.[2] The product is a small-molecule prescription injectable, not a biologic.

Its principal FDA regulatory characteristics are:

Regulatory issue	Assessment
Reference product	Reclast
Active ingredient	Zoledronic acid
Application type	NDA
Generic pathway	ANDA
Biosimilar pathway	Not applicable
Original approval	2007
New-drug exclusivity	Expired
Current market structure	Brand plus generic injectable competition
Main approval risk	Injectable quality, bioequivalence, facility, and supply compliance

Generic zoledronic acid injections may generally rely on the reference product through the ANDA pathway if they meet applicable requirements for active ingredient, dosage form, strength, route, quality, and labeling.

What is the Orange Book status of Reclast?

Reclast's commercial protection is no longer based on active new-drug exclusivity. The principal market barrier is generic product approval and manufacturing execution rather than an unexpired basic formulation patent.

The FDA Orange Book should be reviewed for the current NDA 021817 listing and any patent certifications associated with marketed generic applications.[3] For a generic applicant, relevant legal work includes:

• identifying any active listed patents;
• determining whether a Paragraph IV certification is required;
• evaluating label carve-outs for patented methods of use;
• reviewing pediatric exclusivity, if any;
• assessing 180-day exclusivity exposure from an earlier Paragraph IV filer.

Are Paragraph IV challenges relevant to Reclast?

Paragraph IV risk is limited compared with high-value oral medicines because the main Reclast exclusivity period has expired and multiple generic zoledronic acid products have entered the market.

For a new generic applicant, the more relevant issues are:

1. Whether any Orange Book patent remains listed against the reference product.
2. Whether a generic label must omit a patented indication or dosing instruction.
3. Whether prior ANDA approvals create an effective filing-date advantage for another applicant.
4. Whether the applicant can obtain tentative or final approval before the target commercial launch date.

A Paragraph IV strategy would have greater value if a residual formulation, container, or method-of-use patent remained enforceable. The economic return is likely lower than in markets with one or two active patents protecting a high-revenue product.

When does Reclast lose exclusivity?

Reclast's new-drug exclusivity expired years ago. The product received FDA approval in August 2007, and the applicable period of three-year exclusivity for certain new clinical investigations would not extend beyond 2010.[2]

Patent protection for the underlying zoledronic acid technology also predates the Reclast approval and is not the principal current barrier to generic entry. The commercial timeline is therefore:

Event	Timing
Reclast FDA approval	2007
Three-year regulatory exclusivity	Expired around 2010
Generic development window	Open for many years
Generic market entry	Established
Current competitive issue	Price, supply, quality, and contracting

Exact patent expiration analysis should distinguish patents covering zoledronic acid itself from patents covering specific medical uses, formulations, or manufacturing processes. A historical compound patent does not automatically protect the current Reclast presentation.

What formulations are protected by Reclast's excipient strategy?

The reference formulation is protected commercially by product know-how and regulatory comparability more than by a differentiated excipient patent estate.

The key technical attributes include:

• 5 mg zoledronic acid in 100 mL;
• aqueous ready-to-use presentation;
• citrate-buffered solution;
• mannitol-containing tonicity system;
• preservative-free single-dose packaging;
• controlled pH and impurity profile;
• compatibility with intravenous administration;
• stability through labeled storage conditions.

A generic company seeking ANDA approval would usually favor the reference excipient profile because it reduces formulation-development risk. The closer the formulation is to the reference product, the less likely the applicant is to create new safety, compatibility, or inactive-ingredient questions.

Can a company use different excipients?

Possibly, but injectable products face stricter controls than many oral dosage forms. FDA regulations require inactive ingredients in an ANDA to be the same as those in the reference listed drug, subject to applicable exceptions and justification.[4]

A different excipient could trigger:

• additional safety justification;
• extractables and leachables studies;
• compatibility testing;
• altered pH or osmolality;
• new impurity pathways;
• revised stability work;
• regulatory questions on formulation sameness;
• potential use of a 505(b)(2) pathway instead of a conventional ANDA.

For this product, a new excipient system is unlikely to produce a defensible commercial advantage unless it solves a measurable manufacturing or administration problem.

How strong is the patent estate for Reclast?

The patent estate is relatively weak as a current commercial barrier.

Patent category	Current commercial importance
Basic zoledronic acid compound patents	Low if expired
Oral or intravenous use patents	Potentially relevant only if active and properly listed
Reclast-specific excipient patent	No major publicly recognized barrier identified
Container-closure patents	Potentially relevant to a particular supplier, not the molecule
Manufacturing process patents	Possible niche barrier
Trade secrets	Relevant to scale-up, impurity control, and fill-finish
Regulatory exclusivity	Expired

The strongest defensible assets for a new entrant would likely be process patents or know-how covering impurity control, high-throughput sterile filling, container compatibility, or long-term stability. Those assets would protect manufacturing economics rather than prevent all generic competition.

What manufacturing and intellectual-property barriers affect zoledronic acid injection?

The formulation is simple, but the product is not operationally simple. Important barriers include:

Sterile manufacturing

The product requires sterile compounding, filtration, filling, container closure, inspection, and release testing. A manufacturer must control:

• endotoxins;
• visible and subvisible particles;
• bioburden;
• sterility assurance;
• fill-volume accuracy;
• container-closure integrity;
• elemental impurities;
• degradation products.

A facility with limited sterile injectable capacity may face higher development and launch costs than a company manufacturing a conventional oral generic.

Container-closure compatibility

The product can be packaged in a flexible infusion bag or another suitable sterile container. Commercial evaluation should include:

• PVC versus non-PVC materials;
• sorption or adsorption of zoledronic acid;
• citrate and mannitol compatibility;
• particulate generation;
• extractables and leachables;
• transport stress;
• overwrap requirements;
• administration-set compatibility.

Container selection can create a meaningful cost or supply advantage. A second-source bag and closure system can reduce disruption risk, particularly during hospital and group-purchasing tenders.

Stability and storage

A commercially attractive product must maintain assay, impurities, pH, appearance, sterility, and container integrity through the proposed shelf life. Stability work should cover long-term, accelerated, shipping, freeze-thaw where relevant, and in-use conditions.

Extended stability can improve inventory management, but it must be supported by the approved data package. A longer shelf life alone is unlikely to command a substantial price premium in a generic tender market.

What commercial opportunities exist in Reclast excipients?

The most credible opportunities are incremental.

1. Lower-cost ready-to-use manufacturing

A company can compete by improving yield, reducing rejects, and using a qualified multi-source supply chain for mannitol, sodium citrate, bags, ports, and overwraps.

2. Container-closure differentiation

A supplier could offer a non-PVC or lower-extractables presentation, provided it remains compliant with the relevant ANDA or regulatory pathway. Hospitals may value standardized infusion bags and compatibility with existing administration systems.

3. Supply reliability

Zoledronic acid injection is administered in clinics, hospitals, and outpatient infusion centers. Buyers may prioritize dependable availability over minor formulation differences. Dual-source excipient and packaging qualification can support contracting.

4. Private-label and contract manufacturing

The product is suitable for partnerships involving:

• generic pharmaceutical companies;
• hospital purchasing organizations;
• specialty injectable distributors;
• contract sterile-fill manufacturers;
• regional pharmaceutical suppliers.

The opportunity is stronger for companies with existing sterile injectable infrastructure than for excipient companies attempting to create a standalone proprietary formulation.

5. Global geographic expansion

Regulatory requirements differ across the United States, European Union, Canada, Latin America, and emerging markets. A common formulation and container platform can reduce development cost, but labeling, stability, pharmacopoeial, and packaging requirements must be assessed jurisdiction by jurisdiction.

6. Combination commercial services

The excipient itself is unlikely to support premium pricing. Commercial value may come from bundled services such as ready-to-administer supply, inventory programs, cold-chain or room-temperature logistics where permitted, and reliable delivery to infusion networks.

How does Reclast compare with Zometa?

Reclast and Zometa contain zoledronic acid but serve different clinical and commercial segments.

Attribute	Reclast	Zometa
Main therapeutic area	Osteoporosis and Paget's disease	Oncology-related indications
Common dose	5 mg	4 mg, subject to indication and regimen
Administration	Intravenous infusion	Intravenous infusion
Market buyers	Osteoporosis clinics, hospitals, infusion centers	Oncology practices and hospitals
Excipient opportunity	Limited	Limited
Regulatory risk	Injectable ANDA requirements	Injectable ANDA and oncology-label requirements
Commercial differentiator	Ready-to-use convenience and supply	Oncology distribution, dosing, and contracting

The two products should not be treated as interchangeable commercial products. Different indications, dosing schedules, warnings, renal restrictions, and labeling requirements affect regulatory strategy and market access.

Which companies are challenging Reclast?

The generic market includes multiple manufacturers of zoledronic acid injection. The competitive set can include large generic companies, specialty injectable manufacturers, and regional suppliers. Competition generally centers on:

• wholesale acquisition price;
• hospital contract price;
• availability;
• back-order performance;
• approved presentations;
• packaging format;
• manufacturing-site reliability;
• distributor relationships.

A current company-by-company ranking requires live FDA and market-sales data. The most relevant diligence sources are the FDA Orange Book, Drugs@FDA, FDA drug shortage records, state purchasing data, and hospital group-purchasing contracts.[3,5]

What generic entry risks exist for Reclast?

Generic entry risk is high because:

• regulatory exclusivity has expired;
• the formulation uses common excipients;
• the active ingredient is chemically defined;
• the product has a straightforward 5 mg/100 mL presentation;
• multiple sterile injectable manufacturers can potentially supply it;
• excipient differentiation is limited.

The principal risks for a new entrant are execution risks rather than molecule-level patent risks. These include failed stability, container incompatibility, sterile manufacturing deficiencies, inspection findings, supply interruptions, and weak contracting coverage.

Key Takeaways

• Reclast contains zoledronic acid, mannitol, and sodium citrate in a 5 mg/100 mL ready-to-use intravenous solution.
• Mannitol provides tonicity and formulation support; sodium citrate controls pH and buffering.
• The formulation has limited scope for premium excipient innovation.
• FDA exclusivity has expired, and generic competition is established.
• Reclast has no biosimilar pathway because zoledronic acid is a small molecule.
• The strongest commercial opportunities involve sterile manufacturing, packaging, supply reliability, and contract distribution.
• Alternative excipients may increase ANDA or 505(b)(2) risk without creating a strong market advantage.
• Process know-how, impurity control, container compatibility, and dual sourcing are more valuable than a new excipient concept.
• Revenue exposure is likely concentrated in price-sensitive institutional and infusion-center purchasing rather than branded retail demand.

FAQs

Is mannitol in Reclast clinically active?

No. Mannitol is an inactive ingredient used primarily to support tonicity and the physical properties of the infusion solution.

Can Reclast be reformulated without sodium citrate?

A reformulation may be technically possible, but removing or replacing sodium citrate could alter pH, stability, impurity formation, and regulatory comparability. The change would require formulation and regulatory justification.

Is zoledronic acid injection a biologic?

No. Zoledronic acid is a chemically synthesized small molecule. Generic products use the ANDA pathway rather than the biosimilar pathway.

Can an excipient supplier patent a new Reclast formulation?

Potentially, if the formulation has novelty, non-obviousness, utility, and adequate disclosure. Commercial value would depend on whether the formulation improves stability, manufacturing, packaging, or administration enough to justify development and enforcement costs.

Does a non-PVC infusion bag create a strong market advantage?

Usually not by itself. It may improve procurement appeal, extractables and leachables positioning, or supply flexibility, but the product would still compete in a price-sensitive generic injectable market.

References

1. U.S. Food and Drug Administration. (2024). Reclast (zoledronic acid) injection prescribing information.
2. U.S. Food and Drug Administration. (2007). NDA 021817: Reclast approval letter and regulatory history.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). 21 C.F.R. § 314.94: Content and format of an ANDA.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA and FDA drug shortage database.